Elanco’s results for the second quarter were positively received by the market, reflecting momentum across both its Pet Health and Farm Animal businesses. Management attributed growth to strong execution in the U.S. and international markets, particularly the success of new products like Zenrelia and Credelio Quattro. CEO Jeffrey Simmons noted that “Zenrelia was the largest contributor to second quarter total Elanco growth,” with broad-based gains from innovative treatments and share gains in core categories such as dermatology and parasiticides. Expanded retail availability and increased market penetration further supported volume and pricing strength.
Is now the time to buy ELAN? Find out in our full research report (it’s free for active Edge members).
Elanco (ELAN) Q2 CY2026 Highlights:
- Revenue: $1.37 billion vs analyst estimates of $1.31 billion (10.2% year-on-year growth, 4.2% beat)
- Adjusted EPS: $0.34 vs analyst estimates of $0.27 (26.5% beat)
- Adjusted EBITDA: $288 million vs analyst estimates of $250.2 million (21.1% margin, 15.1% beat)
- The company lifted its revenue guidance for the full year to $5.12 billion at the midpoint from $5.05 billion, a 1.3% increase
- Management raised its full-year Adjusted EPS guidance to $1.13 at the midpoint, a 6.6% increase
- EBITDA guidance for the full year is $1.02 billion at the midpoint, above analyst estimates of $1.00 billion
- Operating Margin: 8%, up from 6.8% in the same quarter last year
- Constant Currency Revenue rose 8% year on year, in line with the same quarter last year
- Market Capitalization: $11.36 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Elanco’s Q2 Earnings Call
- Glen Santangelo (Barclays) asked about pricing dynamics for Zenrelia and Quattro amid competitive pressures; CEO Jeffrey Simmons emphasized responsible pricing and durable demand, noting, “With portfolio value and differentiation, you can take price.”
- Jonathan Block (Stifel) asked for clarity on the revenue contribution of Zenrelia and Credelio Quattro; CFO Robert VanHimbergen highlighted broad-based growth but noted the innovation basket was the key driver on a stable base.
- Daniel Clark (Leerink) questioned the sustainability of Zenrelia’s first-line usage and messaging; Simmons pointed to growing veterinarian confidence and “best medicine” positioning driving increased penetration.
- Michael Ryskin (Bank of America) asked about the runway for Quattro and Zenrelia and the payoff from DTC investment; management cited ongoing clinic penetration and an “unbelievable” correlation between DTC marketing spend and market share gains.
- Umer Raffat (Evercore ISI) inquired about operating expense trends and leverage; VanHimbergen projected operating margin improvement as Project Ascend scales, with continued investment in launch support and marketing.
Catalysts in Upcoming Quarters
In the quarters ahead, the StockStory team will be watching (1) the pace at which Befrena overcomes supply constraints and scales in the U.S. and international markets, (2) continued market share gains and clinic penetration for Zenrelia and Credelio Quattro, and (3) the impact of Elanco Ascend’s cost savings and automation on margin improvement. Progress on global launches and sustained farm animal segment momentum will also be important markers of ongoing execution.
Elanco currently trades at $22.75, down from $25.60 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.
But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.